Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
42
Journal Issue
2
Date Issued
2024-01-10
Author(s)
Garon, Edward B
Lu, Shun
Goto, Yasushi
De Marchi, Pedro
Paz-Ares, Luis
Spigel, David R
Thomas, Michael
Ardizzoni, Andrea
Barlesi, Fabrice
Orlov, Sergey
Yoshioka, Hiroshige
Mountzios, Giannis
Khanna, Sadhvi
Bossen, Claudia
Carbini, Mariana
Turri, Sabine
Myers, Andrea
Cho, Byoung Chul
Abstract
Effective treatments for resectable non-small-cell lung cancer (NSCLC) are limited and relapse rates are high. The interleukin (IL)-1β pathway has been linked with tumor development and progression, including in the Canakinumab Anti-Inflammatory Thrombosis Outcomes cardiovascular study in which IL-1β pathway inhibition with canakinumab reduced lung cancer incidence and mortality in an exploratory analysis.
SDGs
Type
journal article